Themis Medicare Approves Preferential Issue of 45,95,795 Convertible Equity Warrants at Rs. 100 Each

Themis Medicare Limited's Preferential Issue Committee held a crucial meeting on February 25, 2026, to deliberate on the company's proposed preferential issue of convertible equity warrants. The committee, constituted by the Board of Directors, approved key decisions regarding the allotment and pricing of these financial instruments. Warrant Allotment Details The committee approved the allotment of convertible equity warrants to Vividhmargi Investments Private Limited, a decision that builds upon the Board's earlier approval from February 13, 2026. The pricing structure was established based on professional certification and regulatory compliance requirements. Parameter: Details Allottee: Vividhmargi Investments Private Limited Number of Warrants: 45,95,795 Minimum Issue Price: Rs. 99.76 Final Issue Price: Rs. 100.00 per warrant Pricing Certification: Mr. Abhishek Wagh, Practicing Company Secretary Regulatory Compliance and Pricing The committee noted the pricing certificate issued by Mr. Abhishek Wagh, Proprietor of M/s. Abhishek Wagh & Associates, Practicing Company Secretaries. This certificate indicated the minimum issue price of Rs. 99.76 in accordance with Regulation 164 of the SEBI (ICDR) Regulations, 2018. The committee subsequently approved rounding up this price to Rs. 100.00 per convertible equity warrant for practical implementation. Postal Ballot Schedule The committee approved the Notice of Postal Ballot to seek shareholder approval for the preferential issue. The approval process is subject to consent from both shareholders and stock exchanges, reflecting the company's commitment to regulatory compliance. Event: Date Relevant Date of Preferential Issue: February 25, 2026 Dispatch of Notice of Postal Ballot: February 25, 2026 Starting of E-voting and Postal Ballot: February 26, 2026 Ending of E-voting and Postal Ballot: March 27, 2026 Corporate Governance Framework The meeting was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's adherence to disclosure requirements. Chairman and Director Dinesh S. Patel signed the disclosure document, ensuring proper authorization and accountability in the decision-making process. This preferential issue represents a significant corporate action for Themis Medicare Limited, requiring comprehensive stakeholder approval before implementation. The structured approach to pricing, allotment, and approval processes reflects the company's commitment to regulatory compliance and transparent corporate governance practices. Themis Medicare Limited has announced a key management change with the resignation of its Company Secretary and Compliance Officer. The pharmaceutical company informed the stock exchanges about this corporate development under regulatory disclosure requirements. Key Personnel Change Mr. Pradeep M. Chandan has resigned from his position as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) of Themis Medicare Limited. The resignation became effective from February 13, 2026. Position Details: Information Name: Pradeep M. Chandan Positions Held: Company Secretary, Compliance Officer & KMP Effective Date: February 13, 2026 Reason: Other professional commitments Regulatory Communication The company formally communicated this development to both major stock exchanges on February 14, 2026. The notification was sent to BSE Limited (Scrip Code: 530199) and National Stock Exchange of India Limited (Symbol: THEMISMED) under reference number TML/BSE/NSE/2025-26/52. Official Statement In his resignation letter dated February 12, 2026, Mr. Chandan stated that he was resigning due to other professional commitments. He requested the Board of Directors to accept his resignation and relieve him from his position with immediate effect. The outgoing Company Secretary expressed sincere gratitude to the management and Board of Directors for their support, guidance, and cooperation during his tenure. Company Leadership The resignation notification was signed by Mr. Dinesh S. Patel, Chairman & Director (DIN: 00033273), confirming the company's compliance with regulatory disclosure requirements under Regulation 30. The company will need to appoint a new Company Secretary and Compliance Officer to fill the vacant positions in accordance with regulatory requirements. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.